Clinical Trials
82 trialsNCT06632977 2026-06-02
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06225596 2026-05-27
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2 Active not recruiting
NCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT04322318 2026-05-05
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
NCT05005728 2026-05-05
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT03517969 2026-04-23
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04709276 2026-04-06
CHAMP
Duke University
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03263650 2026-02-17
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02955082 2026-02-04
BARCODE2
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT05806515 2026-01-29
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
SWOG Cancer Research Network
Phase 2 Recruiting
NCT03937843 2026-01-20
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT06039371 2026-01-14
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
Phase 2 Recruiting
NCT04592237 2025-12-23
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05975307 2025-12-01
BCIRT-01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT06738303 2025-08-27
CATCH-177
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04038502 2025-08-20
COBRA
VA Office of Research and Development
Phase 2 Recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07043972 2025-07-20
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05312671 2025-06-29
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03442556 2025-06-12
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Phase 2 Terminated
NCT04871529 2024-12-30
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
SWOG Cancer Research Network
Phase 2 Terminated
NCT00936936 2024-08-26
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05563558 2024-06-11
PEAPOD_FOS
Fundacion Oncosur
Phase 2 Recruiting
NCT03451331 2024-05-16
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03390595 2023-10-18
INDUCOMAIN
Associació per a la Recerca Oncologica, Spain
Phase 2 Completed
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT00077129 2023-06-18
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02598895 2022-11-17
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
Phase 2 Completed
NCT00432094 2022-05-17
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT05030077 2021-09-01
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT02985021 2021-08-05
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Seattle Institute for Biomedical and Clinical Research
Phase 2 Terminated
NCT02860819 2021-03-03
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer
National Cancer Institute, Slovakia
Phase 2 Completed
NCT01051570 2020-12-01
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00049257 2020-09-01
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00514540 2020-09-01
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02311764 2020-01-23
PRO-PLAT
Cantonal Hospital of St. Gallen
Phase 2 Terminated
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT00467051 2018-08-29
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT00002943 2018-08-10
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00461851 2017-12-14
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Yale University
Phase 2 Completed